NCT02753114View on ClinicalTrials.gov

Prehospital Analgesia With Intra-Nasal Ketamine

PHASE4CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

November 6, 2017

Primary Completion Date

May 24, 2018

Study Completion Date

May 24, 2018

Conditions
PainAcute Pain
Interventions
DRUG

Ketamine

Intranasal Ketamine administered via mucosal atomization device at 0.5 - 1 mg / kg IN.

DRUG

Normal Saline

Intranasal Normal Saline administered via mucosal atomization device.

Trial Locations (1)

V3V 1Z2

British Columbia Emergency Health Services Station 249, Surrey

All Listed Sponsors
collaborator

British Columbia Emergency Health Services

UNKNOWN

lead

University of British Columbia

OTHER

NCT02753114 - Prehospital Analgesia With Intra-Nasal Ketamine | Biotech Hunter | Biotech Hunter